Daniel M Fass

US Patent:

20110200686, Aug 18, 2011

Filed:

Apr 7, 2009

Appl. No.:

12/936695

Inventors:

Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Cambridge MA, US
Andy J. Chien - Bellevue WA, US

Assignee:

UNIVERSITY OG WASHINGTON - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA

International Classification:

A61K 33/14
A61K 31/4965
A61P 35/00

US Classification:

424677, 51425504

Abstract:

The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating a neoplastic condition in a subject by administering the modulator of the Wnt/βcatenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof to the subject under conditions effective to treat a neoplastic disorder.

US Patent:

20110251144, Oct 13, 2011

Filed:

Sep 16, 2009

Appl. No.:

13/119206

Inventors:

Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US

Assignee:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

A61K 31/7048
A61K 31/663
A61K 31/4406
A61K 31/167
A61K 31/203
A61K 31/424
A61K 31/553
A61K 31/428
A61K 31/52
A61K 31/444
A61K 31/197
A61P 35/00
A61P 19/08
A61P 3/10
A61P 7/00
A61P 25/00
A61P 25/28
A61P 17/14
A61P 1/02
A61P 31/18
A61P 35/02
A61P 25/24
A61K 31/495

US Classification:

514 27, 51425504, 514108, 514357, 514575, 514559, 514375, 51421113, 514367, 5142633, 514334, 514564, 51426337

Abstract:

The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

US Patent:

20120040916, Feb 16, 2012

Filed:

Dec 21, 2009

Appl. No.:

13/141442

Inventors:

Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US

Assignee:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

A61K 38/12
A61K 31/695
A61K 31/12
A61P 43/00
A61K 31/122
A61K 31/517
A61K 31/7034
A61K 31/365
A61K 31/4375

US Classification:

514 211, 514450, 514 63, 514463, 514685, 514279, 514680, 5142664, 514 25

Abstract:

The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/β-catenin pathway by selecting a subject with a condition mediated by the Wnt/β-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly inhibiting the Wnt/β-catenin pathway in a subject is also disclosed.

US Patent:

20120046242, Feb 23, 2012

Filed:

Dec 21, 2009

Appl. No.:

13/141838

Inventors:

Randall T. Moon - Kenmore WA, US
Travis L. BIechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US

Assignee:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

A61K 31/695
A61K 31/497
A61K 31/343
A61K 31/336
A61K 31/4402
A61K 31/015
A61K 31/553
A61K 31/55
A61K 31/4245
A61K 31/506
A61K 31/4406
A61K 31/167
A61K 31/4409
A61K 31/472
A61K 31/69
A61K 31/453
A61K 31/404
A61K 31/427
A61K 31/426
A61P 35/00
A61K 31/5377

US Classification:

514 63, 5142348, 51425212, 514468, 514475, 514277, 514763, 51421108, 51421206, 51421702, 514364, 514470, 514275, 514357, 514619, 514309, 5142352, 514 64, 514326, 514414, 514369

Abstract:

The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

US Patent:

20130039998, Feb 14, 2013

Filed:

Dec 23, 2009

Appl. No.:

13/141747

Inventors:

Daniel Fass - Winchester MA, US
Stephen Haggarty - Dorchester MA, US
Edward Scolnick - Wayland MA, US
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA

International Classification:

A61K 31/167
A61K 31/4406
A61P 25/00
A61K 31/513
A61K 33/14
A61K 33/00
A61K 31/4045
A61K 31/194

US Classification:

424677, 514616, 514415, 514357, 514574, 514274, 424715

Abstract:

The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.

US Patent:

20140080775, Mar 20, 2014

Filed:

Nov 18, 2013

Appl. No.:

14/082810

Inventors:

Stephen Haggarty - Dorchester MA, US
Daniel Fass - Cambridge MA, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA
The General Hospital Corporation - Boston MA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA

International Classification:

A61K 31/428
A61K 31/495
A61K 31/4406
A61K 31/43
A61K 31/203
A61K 31/7048
A61K 31/424
A61K 31/553
A61K 31/663
A61K 31/167

US Classification:

514 27, 514367, 514108, 51425504, 514357, 514575, 514559, 514375, 51421113, 514197

Abstract:

The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.

US Patent:

20110008468, Jan 13, 2011

Filed:

Feb 27, 2010

Appl. No.:

12/660591

Inventors:

Stephen J. Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US
Jennifer Pan - Acton MA, US
Josh Ketterman - Cambridge MA, US
Edward Holson - Newton Highlands MA, US
Tracey Lynn Petryshen - Cambridge MA, US
Michael C. Lewis - Boston MA, US

International Classification:

A61K 33/00
A61K 31/407
A61K 31/4545
A61K 31/404
A61K 31/553
A61K 31/506
A61P 25/00

US Classification:

424715, 424722, 514410, 514318, 514414, 51421108, 514275

Abstract:

Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.

US Patent:

20170049793, Feb 23, 2017

Filed:

May 1, 2015

Appl. No.:

14/701936

Inventors:

Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Daniel Fass - Winchester MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA

International Classification:

A61K 31/708
A61K 31/353
A61K 31/7048
A61K 31/357
A61K 31/506
A61K 31/4406
A61K 31/167
A61K 31/196
A61K 31/24
A61K 31/4409
A61K 31/472
A61K 31/5377
A61K 31/69
A61K 31/15
A61K 31/495
A61K 31/426
A61K 31/52
A61K 31/404
A61K 31/405
A61K 31/4178
A61K 31/4439
A61K 31/047
A61K 31/695
A61K 31/407
A61K 31/403
A61K 31/421
A61K 31/5383
A61K 31/351
A61K 31/4152
A61K 31/166
A61K 31/585
A61K 31/57
A61K 31/565
A61K 31/365
A61K 31/201
A61K 31/336
A61K 31/4402
A61K 31/015
A61K 31/366
A61K 31/553
A61K 31/5575
A61K 31/55
A61K 31/27
A61K 31/4245
A61K 31/352

Abstract:

The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.